These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 29600441)

  • 1. Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
    Faissner S; Gold R
    CNS Drugs; 2018 Mar; 32(3):269-287. PubMed ID: 29600441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune therapy of multiple sclerosis--future strategies.
    Meuth SG; Göbel K; Wiendl H
    Curr Pharm Des; 2012; 18(29):4489-97. PubMed ID: 22612746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.
    Melzer N; Meuth SG
    Clin Exp Immunol; 2014 Mar; 175(3):359-72. PubMed ID: 24032475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Treatment for Multiple Sclerosis; Current New Drugs Specific for Multiple Sclerosis.
    TaŞKapilioĞLu Ö
    Noro Psikiyatr Ars; 2018; 55(Suppl 1):S15-S20. PubMed ID: 30692849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying agents in multiple sclerosis.
    O'Connor PW; Oh J
    Handb Clin Neurol; 2014; 122():465-501. PubMed ID: 24507532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New aspects of immunotherapy in multiple sclerosis].
    Pape K; Zipp F; Bittner S
    Nervenarzt; 2018 Dec; 89(12):1365-1370. PubMed ID: 29881971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of multiple sclerosis - success from bench to bedside.
    Tintore M; Vidal-Jordana A; Sastre-Garriga J
    Nat Rev Neurol; 2019 Jan; 15(1):53-58. PubMed ID: 30315270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Emerging therapies for multiple sclerosis].
    de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
    Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Therapies for Multiple Sclerosis.
    Faissner S; Gold R
    Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis.
    Napier J; Rose L; Adeoye O; Hooker E; Walsh KB
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):7-15. PubMed ID: 30702002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.
    De Kleijn KMA; Martens GJM
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New biological agents in the treatment of multiple sclerosis.
    Buc M
    Bratisl Lek Listy; 2018; 119(4):191-197. PubMed ID: 29663814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.